MedTrace Logo

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

NCT04421560 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2026-02-20

No results posted yet for this study

Summary

This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL).

The three drugs being used in the study are:

* Pembrolizumab (MK3475)
* Ibrutinib
* Rituximab (or biosimilar)

Conditions

Interventions

DRUG

Ibrutinib

Capsule, taken by mouth daily

DRUG

Pembrolizumab

Given as an intravenous injection through a vein (IV) every 3 weeks

DRUG

Rituximab

Given as infusion into a vein (intravenous, IV)

Sponsors & Collaborators

Principal Investigators

  • Lakshmi Nayak, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2026-12-05
Completion
2027-01-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04421560 on ClinicalTrials.gov